中国生物制药创新药III期研究取得阳性结果

北京商报12-18 19:01

北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。　　该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。集团已与中国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492901547?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-18 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492901547","market":"us","top_or_hot":-1,"title":"中国生物制药创新药III期研究取得阳性结果","media":"北京商报","content":"<div>\n<p>北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。　　该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。集团已与中国...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202412183272216750.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药创新药III期研究取得阳性结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药创新药III期研究取得阳性结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 19:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202412183272216750.html><strong>北京商报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。　　该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。集团已与中国...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202412183272216750.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"http://finance.eastmoney.com/a/202412183272216750.html","article_id":"2492901547","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412183272216750.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492901547","pubTimestamp":1734519698,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","BK1515":"抗疫概念","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1574":"生物医药B类股","BK1161":"生物科技","01177":"中国生物制药","III":"信息服务","BK4134":"信息科技咨询与其它服务","06978":"永泰生物-B"},"translate_title":"Phase III study of innovative biopharmaceutical drugs in China achieves positive results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"06978":1,"III":1},"content_text":"北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。　　该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。集团已与中国国家药品监督管理局药品审评中心（CDE）沟通，并获得书面同意提交上市申请。集团将于近期递交上市申请。（文章来源：北京商报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492901547"}